Results 21 to 30 of about 27,163 (253)

T Helper Cells: The Modulators of Inflammation in Multiple Sclerosis [PDF]

, 2020
Multiple sclerosis (MS) is a chronic neurodegenerative disease characterized by the progressive loss of axonal myelin in several areas of the central nervous system (CNS) that is responsible for clinical symptoms such as muscle spasms, optic neuritis ...
Amormino, Carola, Frascolla, Simone, Kunkl, Martina, Tuosto, Loretta, Volpe, Elisabetta   +4 more
core   +1 more source

FTY720 (fingolimod) modulates the severity of viral-induced encephalomyelitis and demyelination. [PDF]

, 2014
BackgroundFTY720 (fingolimod) is the first oral drug approved by the Food and Drug Administration for treatment of patients with the relapsing-remitting form of the human demyelinating disease multiple sclerosis.
Blanc, Caroline A, Lane, Thomas E, Rosen, Hugh   +2 more
core   +1 more source

Sphingosine 1-phosphate receptors: do they have a therapeutic potential in cardiac fibrosis? [PDF]

, 2017
Sphingosine 1-phosphate (S1P) is a bioactive lipid that is characterized by a peculiar mechanism of action. In fact, S1P, which is produced inside the cell, can act as an intracellular mediator, whereas after its export outside the cell, it can act as ...
Frati, Alessia, Meacci, Elisabetta, Monaco, Lucia, Pierucci, Federica, Vestri, Ambra   +4 more
core   +2 more sources

Effectiveness, safety and health-related quality of life of multiple sclerosis patients treated with fingolimod: results from a 12-month, real-world, observational PERFORMS study in the Middle East

BMC Neurology, 2017
Background Evidence on the use of fingolimod in real-world clinical practice and data on patient-reported health-related quality of life (HRQoL) in countries such as the Middle East are sparse.
Anat Achiron, Hany Aref, Jihad Inshasi, Mohamad Harb, Raed Alroughani, Mahendra Bijarnia, Kathryn Cooke, Ozgur Yuksel   +7 more
doaj   +1 more source

Aligned Fingolimod-Releasing Electrospun Fibers Increase Dorsal Root Ganglia Neurite Extension and Decrease Schwann Cell Expression of Promyelinating Factors

Frontiers in Bioengineering and Biotechnology, 2020
Researchers are investigating the use of biomaterials with aligned guidance cues, like those provided by aligned electrospun fibers, to facilitate axonal growth across critical-length peripheral nerve defects. To enhance the regenerative outcomes further,
Devan L. Puhl, Devan L. Puhl, Jessica L. Funnell, Jessica L. Funnell, Anthony R. D’Amato, Anthony R. D’Amato, Jonathan Bao, Jonathan Bao, Dmitri V. Zagorevski, Yelena Pressman, Daniel Morone, Daniel Morone, Agnes E. Haggerty, Martin Oudega, Martin Oudega, Martin Oudega, Martin Oudega, Ryan J. Gilbert, Ryan J. Gilbert   +18 more
doaj   +1 more source

Mode of binding, kinetic and thermodynamic properties of a lipid-like drug (Fingolimod) interacting with Human Serum Albumin [PDF]

BioImpacts, 2023
Introduction: Fingolimod is a drug that is used to treat multiple sclerosis (MS). It has pH-dependent solubility and low solubility when buffering agents are present.
Samira Gholizadeh, Hossein Haghaei, Hosna Karami, Somaieh Soltani, Mostafa Zakariazadeh, Javad Shokri   +5 more
doaj   +1 more source

Induced Stem Cells as a Novel Multiple Sclerosis Therapy. [PDF]

, 2016
Stem cell replacement is providing hope for many degenerative diseases that lack effective therapeutic methods including multiple sclerosis (MS), an inflammatory demyelinating disease of the central nervous system. Transplantation of neural stem cells or
Guan, Yang-Tai, Liu, Yan-Qun, Xie, Chong, Zhang, Guang-Xian   +3 more
core   +2 more sources

Fingolimod treatment promotes proliferation and differentiation of oligodendrocyte progenitor cells in mice with experimental autoimmune encephalomyelitis

Neurobiology of Disease, 2015
Multiple sclerosis (MS) is a major demyelinating disease of the central nervous system (CNS) leading to functional deficits. The remyelination process is mediated by oligodendrocyte progenitor cells (OPCs).
Jing Zhang, Zheng Gang Zhang, Yi Li, Xiaoshuang Ding, Xia Shang, Mei Lu, Stanton B. Elias, Michael Chopp   +7 more
doaj   +1 more source

Cyclical and dose-dependent responses of adult human mature oligodendrocytes to fingolimod [PDF]

, 2008
Fingolimod is a sphingosine-1-phosphate (S1P) analogue that has been used in clinical trials as a systemic immunomodulatory therapy for multiple sclerosis. Fingolimod readily accesses the central nervous system, raising the issue of its direct effects on
Agrawal, Alabed, Ancellin, Beer, Betty Soliven, Billich, Coelho, D'Souza, Davis, Dawson, Foster, Franklin, Gardell, Gensert, Goetzl, Graeler, Gräler, Jack, Jack P. Antel, Jaillard, Jeffery A. Hall, Jin, Jung, Kappos, Kataoka, Kim, Lajtha, Lan, Lassmann, Lee, Liu, Mandala, Matloubian, Miron, Miron, Niedernberg, Niedernberg, Novgorodov, Park, Sanchez, Sawicka, Sherman, Simons, Sloane, Smith, Terai, Timothy E. Kennedy, Toman, Veronique E. Miron, Webb, Wosik, Yong, Yu   +52 more
core   +2 more sources

Fingolimod Inhibits Inflammation but Exacerbates Brain Edema in the Acute Phases of Cerebral Ischemia in Diabetic Mice

Frontiers in Neuroscience, 2020
Background and Purpose: Diabetes mellitus increases stroke incidence and mortality and hampers functional recovery after stroke. Fingolimod has been shown to improve neurofunctional recovery and reduce brain infarction after ischemic injury in mice ...
Wanlu Li, Tingting He, Tingting He, Lu Jiang, Rubing Shi, Yaying Song, Yaying Song, Muyassar Mamtilahun, Yuanyuan Ma, Yuanyuan Ma, Zhijun Zhang, Yaohui Tang, Guo-Yuan Yang, Guo-Yuan Yang, Yongting Wang   +14 more
doaj   +1 more source